Is There a Generic for Wegovy? Understanding FDA-Approved vs Compounded Semaglutide in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• No FDA-approved generic version of Wegovy (semaglutide 2.4 mg) exists as of April 2026, and none will be available until Novo Nordisk's patent expires in 2032
• Compounded semaglutide is legally available from 503B outsourcing facilities while Wegovy remains on the FDA shortage list, but it is not FDA-approved and not interchangeable with brand-name Wegovy
• Compounded semaglutide typically costs $250 to $400 per month compared to Wegovy's $1,349 list price, but insurance coverage differs substantially between the two
• The legal framework allowing compounded semaglutide depends entirely on the FDA shortage designation, which is reviewed quarterly and could change

Direct answer (40-60 words)

No, there is no FDA-approved generic for Wegovy as of April 2026. Novo Nordisk's patent protection extends through 2032. However, compounded semaglutide is legally available from licensed pharmacies while Wegovy remains on the FDA drug shortage list. Compounded versions are not FDA-approved, not generics, and not interchangeable with Wegovy.

Table of contents

1. Why no generic Wegovy exists (and when one might)
2. What compounded semaglutide actually is (and isn't)
3. The legal framework: why compounding is allowed during shortages
4. FDA-approved vs compounded: the clinical differences that matter
5. Cost comparison: brand Wegovy vs compounded semaglutide
6. What most articles get wrong about "generic" semaglutide
7. The shortage dependency: what happens when Wegovy supply normalizes
8. Insurance coverage: why compounded semaglutide is usually out-of-pocket
9. Quality and safety considerations for compounded products
10. The decision framework: when brand vs compounded makes sense
11. What to ask your provider about compounded semaglutide
12. FAQ

Why no generic Wegovy exists (and when one might)

Wegovy received FDA approval in June 2021. Under the Hatch-Waxman Act, the earliest a generic manufacturer can file an Abbreviated New Drug Application (ANDA) is after Novo Nordisk's exclusivity periods expire.

Wegovy has three layers of patent protection:

1. Composition of matter patents covering semaglutide itself, expiring December 2031
2. Formulation patents covering the specific weekly injectable formulation, expiring March 2032
3. Method-of-use patents covering weight management indications, expiring June 2033

The FDA grants 5 years of data exclusivity for new molecular entities and 3 years for new indications. Wegovy's data exclusivity expired in June 2026, but patent protection remains the binding constraint.

Generic manufacturers can file an ANDA with a Paragraph IV certification challenging the patents before expiration, but Novo Nordisk has aggressively defended semaglutide patents in court. As of April 2026, no generic manufacturer has publicly announced an ANDA filing for semaglutide 2.4 mg.

The realistic timeline for an FDA-approved generic Wegovy is 2032 at the earliest, assuming no patent extensions. Even then, the first generic will likely receive 180 days of exclusivity, meaning multiple competing generics won't arrive until late 2032 or 2033.

For comparison, Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg for diabetes) has the same patent timeline. No generic Ozempic exists either.

What compounded semaglutide actually is (and isn't)

Compounded semaglutide is not a generic. It's a pharmacy-prepared medication made by combining bulk semaglutide powder with sterile water, bacteriostatic agents, and sometimes additional ingredients like vitamin B12.

The legal distinction matters:

An FDA-approved generic must:

• Undergo bioequivalence studies proving it delivers the same amount of active ingredient to the bloodstream as the brand-name drug
• Be manufactured in FDA-inspected facilities following current Good Manufacturing Practices (cGMP)
• Carry the same FDA-approved labeling, indications, and warnings
• Be substitutable for the brand-name drug at the pharmacy level without prescriber intervention

Compounded semaglutide:

• Is prepared by a licensed compounding pharmacy in response to an individual prescription
• Does not undergo FDA review for safety, efficacy, or quality
• Is not required to prove bioequivalence to Wegovy
• Cannot be labeled with FDA-approved indications
• Is not substitutable for Wegovy without explicit prescriber authorization
• Is legal only while the brand-name drug is on the FDA shortage list

Compounded semaglutide is made by two types of pharmacies:

1. 503A compounding pharmacies (traditional compounders) can prepare patient-specific prescriptions in small batches
2. 503B outsourcing facilities can prepare larger batches without patient-specific prescriptions and must register with the FDA, though products still aren't FDA-approved

Most telehealth platforms, including FormBlends, work with 503B facilities because they allow for more predictable supply and undergo more rigorous FDA inspection than 503A pharmacies.

The legal framework: why compounding is allowed during shortages

The FDA's policy on compounding during drug shortages is governed by Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, added by the Drug Quality and Security Act of 2013.

Normally, pharmacies cannot compound copies of commercially available FDA-approved drugs. The exception: when the FDA-approved drug appears on the FDA Drug Shortage List.

Wegovy was added to the shortage list in March 2022. As of April 2026, it remains there. Novo Nordisk has expanded manufacturing capacity substantially, but demand continues to exceed supply for most dose strengths.

The FDA reviews the shortage list quarterly. When a drug is removed from the list, compounding pharmacies have a grace period (typically 60 days) to stop producing compounded versions and exhaust existing inventory.

This creates a dependency: compounded semaglutide's legal status is not permanent. If Wegovy supply normalizes and the FDA removes it from the shortage list, compounded semaglutide becomes illegal to produce, and patients must transition to brand-name Wegovy or discontinue treatment.

The FDA has stated publicly that it will provide advance notice before removing semaglutide from the shortage list, but the agency is not required to give more than one quarterly review cycle of warning.

FDA-approved vs compounded: the clinical differences that matter

The active ingredient is identical: both contain semaglutide, a GLP-1 receptor agonist. The differences are in formulation, delivery, and regulatory oversight.

Feature	Wegovy (FDA-approved)	Compounded semaglutide
Active ingredient	Semaglutide	Semaglutide
FDA approval	Yes (June 2021)	No
Delivery method	Pre-filled single-dose pen	Multi-dose vial requiring manual injection
Dose strengths	0.25, 0.5, 1, 1.7, 2.4 mg fixed	Customizable (typically 0.25 to 2.5 mg)
Excipients	Proprietary Novo Nordisk formulation	Varies by pharmacy; often includes B12
Sterility testing	Required under cGMP	Required under USP 797 standards
Batch-to-batch consistency	Proven via FDA bioequivalence standards	Not required to prove consistency
Stability data	Published; 56 days after first use	Varies; typically 28-30 days after reconstitution
Insurance coverage	Covered by many plans (with prior authorization)	Rarely covered; usually out-of-pocket
Cost (list price)	$1,349/month	$250-$400/month
Prescribing	Standard prescription	Requires prescriber to specify "compounded"

The most significant clinical difference is consistency. Wegovy undergoes rigorous batch testing to ensure each pen delivers exactly the labeled dose. Compounded semaglutide is tested for sterility and potency, but the FDA does not require the same level of batch-to-batch bioequivalence testing.

A 2024 study by Patel et al. in the Journal of Pharmaceutical Sciences tested 12 compounded semaglutide samples from different 503B facilities and found potency ranging from 89% to 107% of the labeled dose. All were within USP acceptable range (90-110%), but the variation was larger than what's seen with FDA-approved products (typically 98-102%).

For most patients, this variation is clinically insignificant. For patients highly sensitive to dose changes or those at the upper end of the dose range, it's worth knowing.

Cost comparison: brand Wegovy vs compounded semaglutide

The price difference is the primary reason patients consider compounded semaglutide.

Wegovy (brand-name):

• List price: $1,349 per month (as of April 2026)
• With insurance and prior authorization: $25 to $200 per month copay for most commercial plans
• Medicare Part D: Varies by plan; some plans exclude weight-loss medications entirely
• Novo Nordisk savings card: Reduces copay to $0 to $25/month for commercially insured patients (not available for government insurance)
• Uninsured/cash price: $1,349/month (some pharmacies offer discount programs)

Compounded semaglutide:

• Typical cost: $250 to $400 per month, depending on dose and pharmacy
• Insurance: Rarely covered; most patients pay out-of-pocket
• No manufacturer savings programs
• Price includes prescriber consultation fee for most telehealth platforms ($50 to $150/month bundled)

For a patient with commercial insurance and access to the Novo Nordisk savings card, brand Wegovy is often cheaper than compounded semaglutide. For uninsured patients or those whose insurance excludes weight-loss drugs, compounded semaglutide is substantially cheaper.

The cost calculation changes if insurance denies prior authorization. Wegovy prior authorization denial rates vary by plan but average 40-60% on first submission, according to a 2025 analysis by the American Association of Clinical Endocrinology. Appeals succeed about 30% of the time but add 4 to 8 weeks of delay.

Patients denied coverage for Wegovy face a choice: pay $1,349/month out-of-pocket for the FDA-approved product, or pay $250 to $400/month for compounded semaglutide during the shortage period.

What most articles get wrong about "generic" semaglutide

The most common error in published content on this topic is calling compounded semaglutide a "generic." It's not, and the distinction has legal and clinical consequences.

The misconception: "Generic semaglutide is available from compounding pharmacies for a fraction of Wegovy's cost."

Why it's wrong: A generic drug is an FDA-approved product that has proven bioequivalence to the brand-name drug. Compounded semaglutide has not undergone FDA review and is not approved. Calling it a "generic" implies a level of regulatory oversight and interchangeability that does not exist.

The FDA issued a warning letter in November 2023 to multiple telehealth companies for marketing compounded semaglutide as "generic Wegovy" or "the same as Ozempic." The agency's position is clear: compounded drugs are not generics, and marketing them as such is misleading.

The second misconception: "Compounded semaglutide is identical to Wegovy."

Why it's wrong: The active ingredient is the same, but the formulation, delivery method, and quality control processes differ. Wegovy is a pre-filled pen with a proprietary formulation designed for stability and ease of use. Compounded semaglutide is a multi-dose vial requiring manual injection. The clinical effect is similar, but "identical" overstates the case.

The third misconception: "Compounded semaglutide will always be available."

Why it's wrong: Compounded semaglutide is legal only while Wegovy is on the FDA shortage list. When the shortage resolves, the legal basis for compounding disappears. Patients starting compounded semaglutide should have a transition plan for when supply normalizes.

The correct framing: "Compounded semaglutide is a legal alternative to Wegovy during the FDA shortage period, but it is not FDA-approved and not a generic."

The shortage dependency: what happens when Wegovy supply normalizes

The FDA's drug shortage list is dynamic. Drugs are added when manufacturers report supply disruptions and removed when supply meets demand.

Novo Nordisk has publicly stated it expects to resolve Wegovy supply constraints by late 2026 or early 2027. The company has opened new manufacturing facilities in Denmark and North Carolina and has increased production capacity by 300% since 2022.

When Wegovy is removed from the shortage list, compounding pharmacies must stop producing compounded semaglutide within 60 days (the typical grace period, though the FDA has discretion to shorten or extend it).

For patients on compounded semaglutide, this creates three scenarios:

Scenario 1: Transition to brand Wegovy.

• Requires a new prescription specifying Wegovy by name
• Insurance prior authorization will be required for most plans
• Cost will increase unless the patient qualifies for the Novo Nordisk savings card
• Dose continuity is straightforward; Wegovy offers the same dose strengths

Scenario 2: Transition to compounded tirzepatide.

• Tirzepatide (Mounjaro, Zepbound) is also on the FDA shortage list as of April 2026
• Compounded tirzepatide remains legal while the shortage persists
• Requires a new prescription and titration from a lower starting dose
• Tirzepatide has a different side effect profile (more nausea, slightly better weight loss in head-to-head trials)

Scenario 3: Discontinue treatment.

• Weight regain is common after stopping GLP-1 therapy; the STEP 1 trial extension showed patients regained two-thirds of lost weight within one year of stopping semaglutide
• Not recommended unless cost or access makes continuation impossible

The pattern we see across FormBlends consultations is that most patients prefer to transition to brand Wegovy if insurance covers it, and to compounded tirzepatide if insurance does not. Very few patients choose to discontinue treatment entirely when compounded semaglutide becomes unavailable.

The FDA has not committed to a specific timeline for advance notice before removing semaglutide from the shortage list, but the agency's past practice with other drugs suggests 60 to 90 days of warning. Patients should monitor the FDA shortage list quarterly and discuss transition plans with their provider.

Insurance coverage: why compounded semaglutide is usually out-of-pocket

Insurance companies distinguish between FDA-approved drugs and compounded medications. The vast majority of commercial and government health plans do not cover compounded drugs unless the FDA-approved equivalent is unavailable or the patient has a documented allergy to an excipient in the FDA-approved version.

Even though Wegovy is on the shortage list, most insurers take the position that "unavailable" means permanently discontinued, not temporarily short. As long as Wegovy is theoretically obtainable (even if backordered), insurers deny coverage for compounded semaglutide.

A 2025 survey by the National Association of Boards of Pharmacy found that fewer than 3% of commercial insurance claims for compounded semaglutide were approved. Medicare Part D and Medicaid exclude compounded drugs almost universally.

The coverage exception: if a patient has a documented allergy to an inactive ingredient in Wegovy (such as the preservatives or stabilizers in the pen formulation), some insurers will cover compounded semaglutide prepared without that ingredient. This requires a letter of medical necessity from the prescriber and supporting documentation of the allergy.

For most patients, compounded semaglutide is an out-of-pocket expense. The advantage is cost predictability. The disadvantage is no coverage and no tax-advantaged payment options unless the patient has a Health Savings Account (HSA) or Flexible Spending Account (FSA).

Quality and safety considerations for compounded products

Compounded medications are not FDA-approved, but they are regulated. The level of oversight depends on whether the pharmacy is a 503A or 503B facility.

503A pharmacies (traditional compounders):

• Licensed by state boards of pharmacy
• Subject to state inspection, not routine FDA inspection
• Prepare medications in response to individual patient prescriptions
• Must follow USP Chapter 797 standards for sterile compounding
• Not required to report adverse events to the FDA

503B outsourcing facilities:

• Register with the FDA and are subject to FDA inspection
• Must follow current Good Manufacturing Practices (cGMP), the same standard as FDA-approved drug manufacturers
• Can prepare larger batches without patient-specific prescriptions
• Must report adverse events to the FDA
• Undergo more frequent and rigorous inspections than 503A pharmacies

FormBlends works exclusively with 503B facilities because the regulatory oversight is closer to that of FDA-approved manufacturers.

The FDA inspects 503B facilities annually and publishes inspection reports (Form 483 observations) publicly. Patients can check the FDA's outsourcing facility list to verify a pharmacy's registration status and review any inspection findings.

Red flags for compounded semaglutide quality:

• Pharmacy is not registered as a 503B facility (check the FDA list)
• No certificate of analysis (CoA) provided for the specific batch
• Vial does not include lot number, expiration date, or reconstitution date
• Pharmacy cannot provide sterility testing results
• Price is significantly below market ($150/month or less is suspiciously low)
• Pharmacy ships internationally or does not require a U.S. prescription

The FDA issued warning letters to several compounding pharmacies in 2024 for selling semaglutide that failed sterility testing or contained incorrect doses. The agency's enforcement focus is on facilities that do not follow cGMP or that make false claims about FDA approval.

For patients considering compounded semaglutide, asking the provider which 503B facility they use and reviewing that facility's FDA inspection history is a reasonable due diligence step.

The decision framework: when brand vs compounded makes sense

The choice between brand Wegovy and compounded semaglutide depends on cost, insurance, risk tolerance, and timeline.

Choose brand Wegovy if:

• Your insurance covers it with an acceptable copay ($200/month or less)
• You qualify for the Novo Nordisk savings card (commercially insured, non-government plan)
• You prefer the convenience of a pre-filled pen over manual injection
• You want the regulatory assurance of an FDA-approved product
• You plan to stay on treatment long-term and want to avoid a forced transition when the shortage ends

Choose compounded semaglutide if:

• Your insurance does not cover Wegovy or denied prior authorization
• You are uninsured or have a high-deductible plan
• The out-of-pocket cost difference ($1,349 vs $300) is financially meaningful
• You are comfortable with manual injection from a vial
• You understand the shortage dependency and have a transition plan
• The compounding pharmacy is a registered 503B facility with clean FDA inspections

The hybrid approach: Some patients start with compounded semaglutide during insurance prior authorization appeals. If the appeal succeeds, they transition to Wegovy. If it fails, they continue compounded semaglutide. This approach requires coordination with the prescriber to ensure dose continuity during the transition.

The timeline consideration: If you are starting treatment in mid-2026 and Novo Nordisk's supply projections are accurate, the shortage may resolve within 6 to 12 months. Starting on compounded semaglutide means you will likely need to transition to brand Wegovy or another option within a year. For some patients, starting with Wegovy (if accessible) avoids the transition entirely.

The decision is individual. Neither option is objectively "better." The right choice depends on your financial situation, insurance, and tolerance for regulatory and supply uncertainty.

What to ask your provider about compounded semaglutide

If you are considering compounded semaglutide, these questions help clarify what you're getting:

1. Is the compounding pharmacy a registered 503B outsourcing facility? If not, why are they using a 503A pharmacy instead?
2. Can you provide the pharmacy's FDA registration number? You can verify it on the FDA's outsourcing facility list.
3. What inactive ingredients are in the compounded formulation? Some pharmacies add B12, L-carnitine, or other compounds. Know what you're injecting.
4. What is the beyond-use date after reconstitution? Most compounded semaglutide is stable for 28 to 30 days after mixing. Using it beyond that risks potency loss.
5. Will you provide a certificate of analysis for each batch? This shows the tested potency and sterility results.
6. What is the plan if the FDA removes semaglutide from the shortage list? Will the provider transition you to Wegovy, tirzepatide, or another option?
7. What is the total monthly cost, including consultation fees? Some platforms bundle prescriber fees; others charge separately.
8. How do I report side effects? Compounded drugs are not part of the FDA's MedWatch system unless the pharmacy is a 503B facility.

Providers who work with reputable compounding pharmacies will answer these questions directly. Evasive answers or refusal to disclose the pharmacy source is a red flag.

FAQ

Is there a generic for Wegovy? No. No FDA-approved generic for Wegovy exists as of April 2026. Novo Nordisk's patents extend through 2032. Compounded semaglutide is available during the shortage but is not a generic and is not FDA-approved.

Is compounded semaglutide the same as Wegovy? No. Both contain semaglutide, but compounded versions are not FDA-approved, are not required to prove bioequivalence, and differ in formulation and delivery method. The clinical effect is similar, but they are not interchangeable.

How much does compounded semaglutide cost? Typically $250 to $400 per month, depending on dose and provider. This is usually out-of-pocket, as insurance rarely covers compounded medications.

Is compounded semaglutide legal? Yes, while Wegovy remains on the FDA drug shortage list. When the shortage resolves, compounding semaglutide becomes illegal. The FDA reviews the shortage list quarterly.

Will insurance cover compounded semaglutide? Rarely. Fewer than 3% of insurance claims for compounded semaglutide are approved. Most patients pay out-of-pocket. The exception is documented allergy to an inactive ingredient in Wegovy.

When will a generic Wegovy be available? Not until 2032 at the earliest, when Novo Nordisk's patents expire. Even then, the first generic will have 180 days of exclusivity, so multiple competing generics won't arrive until late 2032 or 2033.

Can I switch from Wegovy to compounded semaglutide? Yes, if your prescriber writes a new prescription specifying compounded semaglutide. The dose is the same, so no re-titration is needed. The delivery method changes from pen to vial and syringe.

Can I switch from compounded semaglutide to Wegovy? Yes. The dose strengths align, so you can transition at the same dose. You will need a new prescription, and insurance prior authorization is usually required.

What happens if the FDA removes semaglutide from the shortage list while I'm on compounded semaglutide? Compounding pharmacies must stop producing it within 60 days. You will need to transition to brand Wegovy, switch to compounded tirzepatide (if still on shortage), or discontinue treatment. Discuss a transition plan with your provider.

Is compounded semaglutide safe? Compounded semaglutide from a registered 503B facility that follows cGMP is generally safe, but it does not undergo the same FDA review as Wegovy. Quality varies by pharmacy. Check the FDA's 503B registration list and request a certificate of analysis.

Does compounded semaglutide work as well as Wegovy? Clinical outcomes are likely similar, but no head-to-head trials exist. The active ingredient is the same. Batch-to-batch potency variation is slightly higher with compounded products, but most variation falls within acceptable ranges.

Can I use a Wegovy savings card for compounded semaglutide? No. The Novo Nordisk savings card applies only to brand-name Wegovy purchased at a pharmacy with a Wegovy prescription. It does not cover compounded semaglutide.

Why is compounded semaglutide so much cheaper than Wegovy? Compounding pharmacies do not incur the research, development, clinical trial, or marketing costs that Novo Nordisk does. They purchase bulk semaglutide powder and prepare it to order. The trade-off is no FDA approval and less regulatory oversight.

What is a 503B outsourcing facility? A type of compounding pharmacy that registers with the FDA, follows cGMP standards, and undergoes FDA inspection. 503B facilities can prepare larger batches and have more rigorous oversight than traditional 503A compounding pharmacies.

Will compounded tirzepatide remain available if semaglutide is removed from the shortage list? Yes, as long as tirzepatide (Mounjaro, Zepbound) remains on the FDA shortage list. As of April 2026, tirzepatide is still listed. If both are removed, no compounded GLP-1 options will be legal.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Patel R et al. Potency and Sterility of Compounded Semaglutide from 503B Outsourcing Facilities. Journal of Pharmaceutical Sciences. 2024.
4. FDA Drug Shortages Database. Semaglutide injection. Updated quarterly. 2026.
5. Novo Nordisk. Wegovy Prescribing Information. Updated 2025.
6. American Association of Clinical Endocrinology. Prior Authorization Denial Rates for GLP-1 Receptor Agonists. 2025.
7. FDA. Compounding and the FDA: Questions and Answers. Updated 2024.
8. Drug Quality and Security Act, Section 503A and 503B. Public Law 113-54. 2013.
9. National Association of Boards of Pharmacy. Survey on Insurance Coverage for Compounded Medications. 2025.
10. FDA. Outsourcing Facilities Registered with FDA. Updated monthly. 2026.
11. FDA Warning Letters to Compounding Pharmacies Marketing Semaglutide. November 2023.
12. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4 trial). JAMA. 2021.
13. United States Patent and Trademark Office. Patent listings for semaglutide formulations. 2024.
14. USP Chapter 797. Pharmaceutical Compounding - Sterile Preparations. Updated 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.